CapEx at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's capex?
- Halozyme Therapeutics (HALO) reported capex of $3.74M in Q1 2026.
- How has Halozyme Therapeutics's capex changed year-over-year?
- Halozyme Therapeutics's capex increased by 293.8% year-over-year, from $950K to $3.74M.
- What is the long-term trend for Halozyme Therapeutics's capex?
- Over 3 years (2021 to 2025), Halozyme Therapeutics's capex has grown at a 68.5% compound annual growth rate (CAGR), from $1.46M to $6.97M.
- What does capex mean?
- Cash spent on physical assets like buildings and equipment.
- How do you interpret capex?
- High capital expenditures suggest expansion or modernization, while low levels may indicate asset-light operations or underinvestment.
- How does capex compare across companies?
- Varies significantly between capital-intensive industries and software/service-based firms.